Ikonisys Inc., a New Haven, Conn.-based diagnostics device firm, has raised $3.8 million of a planned $12 million equity and warrants offering, according to a regulatory filing with the U.S. Securities and Exchange Commission.
Founded in 1999, Ikonisys has developed its CellOptics platform as the basis for automated cell-based diagnostic products. The platform’s technology is designed for rare cell detection, according to the Ikonisys website, and may be used with the company’s Ikoniscope robotic digital microscopy platform in products that detect and monitor cancer, as well as birth defects, such as Down syndrome.
Ikonisys made news two years ago when the U.S. Food and Drug Administration granted approval for the company’s oncoFISH (Fluorescence In Situ Hybridization) HER2 test, intended for the detection of the more aggressive HER2 form of breast cancer.
SOURCE
